(Pending/Targesome):
Two patent applications that relate to development of
targeted anti-angiogenesis therapy for cancer.
US Patent # 6,753,135: "Biological Markers for Evaluating Therapeutic Treatment of Inflammatory and Autoimmune Disorders". (Assigned to SurroMed.)
Susan E. Alters, Alvin Wong, Alshad Lalani, and W.D. Henner, "The targeted cytotoxic prodrug, AQ4N, has significant activity in the breast adenocarcinoma model, MDA-MD-231." Presented at the AACR annual meeting, April, 2006.
Susan E. Alters, Alvin Wong, Alshad Lalani, and W.D. Henner, "The Cytotoxic Prodrug, AQ4N, Demonstrates Tumor Targeting and Accumulation Resulting in Anti-Tumor Activity in the BxPC3 Pancreatic Xenograft Model." Presented at the AACR annual meeting, April, 2006.
Bart A Nijmeijer, Marianke LJ Van Schie, Susan E. Alters, Alvin Wong, Jeffrey L Cleland, Roelof Willemze and J.H. Frederik Falkenburg, "The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia." Presented at the American Society for Hematology annual meeting, December, 2005.
Susan E. Alters, Jeffrey L. Cleland, Alvin Wong and W. David Henner, "The Tissue Targeted Prodrug, AQ4N, is Activated to AQ4 in Murine Tissues and Has Anti-Tumor Efficacy in HCT116 Colon and Panc-1 Pancreatic Carcinoma Xenograft Models." Presented at the AACR/EORTC/NCI meeting, November, 2005.
Jeffrey L. Cleland, Susan E. Alters and Alvin Wong, "The Tissue Targeted Cytotoxic Prodrug, AQ4N, is an Effective Single Agent Therapy in Solid Tumor and Leukemia Models." Presented at the Controlled Release Society meeting, July, 2005.
Susan E. Alters, Alvin Wong, and Jeffrey L. Cleland, "The targeted cytotoxic prodrug, AQ4N, has anti-tumor efficacy in L1210, P388 murine leukemia and namalwa human lymphoma models." Presented at the AACR annual meeting, April, 2005.
Jeffrey L. Cleland, Alvin Wong, and Susan E. Alters, "The targeted cytotoxic prodrug, AQ4N, has comparable activity to standard of care agents in colon and pancreatic cancer models." Presented at the AACR annual meeting, April, 2005.
Jeffrey L. Cleland, Alvin Wong, and Susan E. Alters, "The targeted cytotoxic prodrug, AQ4N, persists in the spleen, large intestine, and subcutaneous tumors." Presented at the AACR annual meeting, April, 2005.
Susan E. Alters, Alvin Wong, and Jeffrey L. Cleland, "A novel N-oxide drug, AQ4N, demonstrates in vitro cytotoxicity on solid tumor and hematopoietic tumor cell lines" Presented at the Experimental Biology annual meeting, April, 2005.
Jeffrey L. Cleland, Alvin Wong, Susan E. Alters, John G. Curd, Robert L. Capizzi, and William D. Henner, "A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues In Vivo." Presented at the American Society for Hematology annual meeting, Dec, 2004.
Susan E. Alters, Pamela D. Garzone, Lingyun Li, Charles A. Wartchow, Tina Doede, John Pease, Julie Trulson and Jeffrey L. Cleland. "Increased Efficacy and Half-life of a Novel Anti-angiogenesis Therapy using αvβ3 Integrin Targeted Dextran Coated Liposomes." Presented at the AACR/NCI/EORTC meeting, Nov., 2003.
Charles A. Wartchow, Susan E. Alters, Lingyun Li, Tina Doede, Susan J. Knox and Jeffrey L. Cleland. "αvβ3 integrin targeted liposomes inhibit tumor growth in vivo." Presented at the Controlled Release Society meeting, July 19, 2003.
Lingyun Li, Susan E. Alters, Charles A. Wartchow, Tina Doede, Jeffrey L. Cleland and Susan J. Knox "A Novel Anti-Angiogenesis Therapy Using Integrin Targeted Nanoparticles." Presented at the Tumor Microenvironment Workshop, May 6, 2003.
Susan E. Alters, "Comprehensive Phenotyping for Asthma/Allergy." Invited talk at the American Association of Asthma Allergy and Immunology meeting, March 2002.
Aaron B. Kantor, Susan E. Alters, Vellalore Kakkanaiah and Lou J. Dietz, "Microvolume Laser Scanning Cytometry Platform for Clinical Studies." Poster at the International Society for Analytical Cytology meeting, May 2002.
Gina L. Costa, Susan E. Alters, Vellalore Kakkanaiah and Aaron B. Kantor, "Phenotypic Profiling of Blood Leukocytes using Microvolume Laser Scanning Cytometry for Autoimmune Disease." Poster at the American Association of Immunology meeting, 2002.
Susan E. Alters, Andrea Perrone, Karen Cheal, Remy Cromer, James R. Snapper and Aaron B. Kantor, "Phenotypic profiling in allergy and asthma: effects of glucocorticosteroids on cell surface and soluble factors." Poster at the Federation of Clinical Immunology Societies meeting, 2001.
Susan E. Alters, Andrea Perrone, Karen Cheal, Remy Cromer, Natalia Tsekhanovskaya, James R. Snapper and Aaron B. Kantor, "Phenotypic Profiling in Asthma and Allergy: Effect of prednisone on cell surface and soluble factors." Poster at the European Asthma Congress, 2001.
Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland, and W.D. Henner, 2007. "Selective Tumor Targeting by the Hypoxia Activated Prodrug, AQ4N, blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer." Clin Cancer Res. 13: 2216.
Charles A. Wartchow, Susan E. Alters, Lingyun Li, Tina Doede, Susan J. Knox and Jeffrey L. Cleland, 2004. "Enhancement of the Efficacy of an Antagonist of an Extracellular Receptor by Attachment to the Surface of a Biocompatible Carrier." Pharm Res. 21:1880.
Aaron B. Kantor, Susan E. Alters, Karen Cheal and Louis Dietz, 2004. "Immune Systems Biology: Immunoprofiling of Cells and Molecules." BioTechniques, 36: 520.
Susan E. Alters, Pedro Avila, Harini Govindarajan, Jun Deng, Homer Boushey and Aaron B. Kantor, 2002. "Phenotypic Profiling of Blood and Airway Secretions in Asthmatic and Healthy Subjects." J. Allergy Clin. Immunol. 109, S340.
Susan E. Alters, Andrea Perrone, Karen Cheal and Aaron B. Kantor, 2001. "Identification of biomarkers in allergy and asthma: effects of glucocorticosteroids on cell surface and soluble factors." J. Allergy Clin. Immunol. 107, S164.
Ramila Philip, Susan E. Alters, Elisa Brunette, Jean Ashton, Jose R. Gadea, Jane Lebkowski and Mohan Philip, 2000. "Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor specific CTL responses in patients with melanoma." J. Immunotherapy 1:168.
Susan E. Alters, Jose R. Gadea, Jane Lebkowski and Ramila Philip, 1999. "IL13 Can Substitute for IL4 in the Generation of Dendritic Cells for Induction of CTL and Gene Therapy", J. Immunotherapy 22:229.
Ramila Philip, Elisa Brunette, Jean Ashton, Susan Alters, Jose R. Gadea, Gerard O'Donoghue, Martin Sorich, Josephine Yau, Jane Lebkowski and Mohan Philip, 1998 "Transgene Expression in Dendritic Cells to Induce Antigen CTL in Healthy Donors", Canc. Gene Therapy 5:236.
Susan E. Alters, Jose R. Gadea, Gerard O'Donoghue, Martin Sorich, Sohel Talib and Ramila Philip, 1998. "Dendritic Cells Pulsed with CEA Peptide Induce CEA-Specific CTL with Restricted TCR Repertoire", J. Immunotherapy 21:17.
Susan E. Alters, Jose R. Gadea and Ramila Philip, 1997. "Immunotherapy of Cancer: Generation of CEA Specific CTL Using CEA Peptide Pulsed Dendritic Cells", Adv. Exp. Med. Biol. 417:519.
Ananda W. Goldrath, Karen E. Chen, Leann Barber and Susan E. Alters, 1995. "Differences in Adhesion Markers, Activation Markers and TcR in Islet Infiltrating vs. Peripheral Lymphocytes in the NOD Mouse", J. Autoimmunity 8:209.
Ananda W. Goldrath, Karen E. Chen, Lamont G. Weide, Parvis M. Pour, Jane S. Lebkowski and Susan E. Alters, 1995. "Retention of Endocrine Function in the SCID-Hu Pancreas Mouse: A Model for the Development of Human Fetal Islet Tissue" , Transplantation 59:1496.
Susan E. Alters, Howard K. Song and C. Garrison Fathman, 1993. "Evidence That Clonal Anergy Is Induced In Thymic Migrant Cells After Anti-CD4 Mediated Transplantation Tolerance." Transplantation 56:633.
Howard K. Song, Susan E. Alters and C. Garrison Fathman, 1993. "Evidence that Anti-CD8 Abrogates Anti-CD4 Mediated Clonal Anergy but Allows Allograft Survival in Mice." Transplantation 55:133.
Lawrence Steinman, William Lindsey, Susan Alters and Suzanne Hodgkinson, 1993. "Anti-CD4 Therapy: From Treatment of Experimental Allergic Encephalomyelitis to Clinical Trials in Multiple Sclerosis," Immunol. Ser. 59:253.
Judy Shizuru, Susan E. Alters and C. Garrison Fathman, 1992. "Anti-CD4 Monoclonal Antibodies in Therapy: Creation of Nonclassical Tolerance in the Adult," Immunol. Rev. 129:105.
Susan E. Alters, Judy Shizuru, Jill Ackerman, Davida Grossman, Karl Seydel and C. G. Fathman, 1991. "Anti-CD4 Mediates Clonal Anergy During Transplantation Tolerance Induction," Journal of Experimental Medicine 173:491.
Karl Seydel, Judith Shizuru, Davida Grossman, Anna Wu, Susan Alters and C.G. Fathman, 1991. "Anti-CD8 Abrogates the Effect of Anti-CD4 Mediated Islet Allograft Survival in a Rat Model," Diabetes 40:1430.
Susan E. Alters, Koichiro Sakai, Lawrence Steinman and Vernon T. Oi, 1990. "Mechanisms of Anti-CD4 Mediated Depletion and Immunotherapy: A Study Using a Set of Chimeric Anti-CD4 Antibodies," Journal of Immunology 14:4587.
Susan E. Alters, Lawrence Steinman and Vernon T. Oi, 1989. "Comparison of Rat and Rat-Mouse Chimeric Anti-Murine CD4 Antibodies In Vitro: Chimeric Antibodies Lyse Low Density CD4+ Cells," Journal of Immunology, 142:2018.
Susan E. Alters, Davida Grossman and C. Fathman, 1992. "Anti-CD4 Mediated Transplantation Tolerance: Mechanisms and Memory." In A Critical Analysis of Monoclonal Antibody Therapy in Transplantation, W. J. Burlingham ed, p.79-99.
Susan E. Alters, Comparison of Rat and Rat-Mouse Chimeric Anti-Murine CD4 Antibodies for Use in Immunotherapy. Doctoral thesis, Stanford University, 1989.